PFCS
SNDX icon

Pale Fire Capital SE’s Syndax Pharmaceuticals SNDX Stock Holding History

Pale Fire Capital SE’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74M Sell
125,550
-158,910
-56% -$3.3M 0.19% 30
2026
Q1 		$6.64M Hold
284,460
– – 0.58% 21
2025
Q4 		$5.98M Buy
+284,460
New +$4.96M 0.4% 20

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Pale Fire Capital SE's SNDX Position: Q2 2026 in Review

Pale Fire Capital SE reduced its Syndax Pharmaceuticals (SNDX) stake by 56% in Q2 2026, selling an estimated $3.3M and leaving 125,550 shares worth $2.74M. The position accounts for 0.19% of the portfolio, ranked #30.

Pale Fire Capital SE first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.64M in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Pale Fire Capital SE held 125,550 shares of Syndax Pharmaceuticals worth $2.74M as of Q2 2026.
  • Pale Fire Capital SE sold 158,910 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.3M.
  • Syndax Pharmaceuticals made up 0.19% of Pale Fire Capital SE's portfolio in Q2 2026, its #30 holding.
  • Pale Fire Capital SE first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pale Fire Capital SE's Syndax Pharmaceuticals position peaked at $6.64M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.